



Professor David Miles
Mount Vernon Cancer Centre, UK



Professor Nadia Harbeck
University of Munich, Germany



Dr Olivier Trédan Léon Bérard Centre, France



Latest advances for patients with HER2+ metastatic breast cancer 7 min



What's available for patients after progression on T-DM1?





Effective adverse event management in clinical practice

10 mir



Key considerations for patients with brain metastases

8 mir



What's the reality of daily life for patients with HER2+ metastatic breast cancer?



Research to reality: Is it possible to go further?



Live Q&A 12 min